Intralesional interferon alfa-2b for the treatment of genital warts.
Am J Obstet Gynecol
; 162(2): 348-54, 1990 Feb.
Article
de En
| MEDLINE
| ID: mdl-2155531
ABSTRACT
A randomized, double-blind, placebo-controlled study has been conducted, and intralesional interferon alfa-2b was tested in the treatment of genital warts. This study design was to give 1 million units interferon alfa-2b intralesionally into the base of each of five external genital warts per patient, on a Monday-Wednesday-Friday treatment schedule for 3 weeks (total of nine injections). Forty-two patients were entered (20 randomized to receive interferon and 22 placebo injections). There were 43.8% of patients on the interferon treatment arm of the double-blind portion of the study who had complete disappearance of all warts, with an additional 25% of patients showing greater than 50% shrinkage of visible warts. On the placebo arm 14.3% showed a complete response, with an additional 14.3% showing greater than 50% shrinkage. This difference between interferon and placebo treatment was statistically significant (p less than 0.03). We conclude that intralesional interferon alfa-2b has significant activity in the treatment of genital warts.
Recherche sur Google
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Condylomes acuminés
/
Interféron de type I
/
Interféron alpha
Type d'étude:
Clinical_trials
Limites:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Langue:
En
Journal:
Am J Obstet Gynecol
Année:
1990
Type de document:
Article